NanoCyclo

Other

NanoCyclo

Atopic Dermatitis/Psoriasis

Preclinical Phase 1 Phase 2 Phase 3
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

NanoCyclo is a nano-encapsulated formulation of cyclosporine, which enables better penetration into the skin layers to provide a local anti-inflammatory effect. Cyclosporine is widely used as a systemic agent to prevent organ transplant rejection and has also been approved to treat autoimmune diseases such as rheumatoid arthritis and psoriasis, and for topical ocular use in the treatment for dry eye and some forms of keratitis. However, cyclosporine does not penetrate the skin and has not been developed as a topical treatment for inflammatory skin diseases like atopic dermatitis and psoriasis. Immune hopes to address this clinical need with NanoCyclo, which is in late stage preclinical development. Preclinical work has demonstrated that NanoCyclo does penetrate into the epidermis and dermis and can produce an anti-inflammatory effect in animal models.